Advani, P. P., Braga, S. A. D. S., Brufsky, A., Giridhar, K., Mayer, E. L., McCann, K. E., O'Regan, R., Manich, C. S., Wander, S. A., Bischof, G. F., Lowenthal, B. H., Bebchuk, J. D., Eli, L. D., Barnett, B., O'Shaughnessy, J., Haddad, T. C. (2025). ALISertib in combination with endocrine therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2–) recurrent or metastatic breast cancer: The phase 2 ALISCA-Breast1 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps1125